NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced that Michael Demurjian, CEO & Chairman, will participate in a panel discussion at the American Urological Association (AUA) Innovation Nexus Conference in Las Vegas, Nevada, taking place on April 25, 2025.
Mr. Demurjian will participate in the panel discussion titled "The Good, the Bad and the Ugly: How to Approach Investors" scheduled for 8:05 - 8:50 a.m. PT on Friday, April 25. As CEO of Aspargo Labs – the company behind HEZKUE®, a first-of-its-kind liquid oral sildenafil suspension already on the market in multiple countries – Mr. Demurjian brings a unique perspective on commercializing innovation in urology and successfully raising capital for groundbreaking products. The panel will be moderated by Andrew Cleeland, BS, CEO of Fogarty Innovation, and will feature fellow panelists Ryan Drant, Founder and Director of Questa Capital Management; Duke Herrell, MD, Founder and CEO of Virtuoso Surgical; and Susan Stimson, BS, Managing Director of KCK Medtech. See full details of the panel discussion here.
“Raising capital in the life sciences is not just about having the right science, it’s about knowing how to navigate the full spectrum of investor dynamics. This means mastering your pitch, articulating why you are the most qualified entrepreneur to implement the business plan and being well-versed in your financial metrics,” said Mr. Demurjian. “Over the course of my career, from Medifast, to co-founding an oncology company where we raised over $50 million and took the company public on Nasdaq, to now leading Aspargo Labs, I have experienced firsthand what truly resonates with investors. I look forward to sharing real-world insights with fellow entrepreneurs at the AUA Innovation Nexus Conference.”
The AUA Innovation Nexus Conference provides a powerful forum for advancing urologic discovery, offering multiple elements such as discussion forums, mentorship opportunities, networking, idea generation, and expertise sharing from business executives. The conference creates an environment for urologic entrepreneurs to network, learn, and explore innovative solutions that improve patient care.
About Aspargo Labs, Inc.
Aspargo Labs, Inc., is a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs' suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. The initial focus is a liquid oral sildenafil suspension currently marketed by Aspargo in multiple countries.
For additional information, please visit our website at www.aspargolabs.com.
FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
For more information:
Aspargo Labs, Inc.
(646) 503-1260
information@aspargolabs.com
Investor & media contacts:
Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
aspargoIR@russopr.com
